CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Ganymed Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes1
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1

Top competitors of Ganymed Pharmaceuticals

List of top competitors of Ganymed Pharmaceuticals based on patent oppositions.